America’s Top Diabetes Drug, Hidden Catch

White tablets spilling from a plastic bottle — Photo: anek jaikui / Shutterstock

Metformin sits in more medicine cabinets than almost any other prescription drug in America, yet most people taking it have never been told exactly how it works or what it demands from their kidneys.

Quick Take

Federal drug labels require doctors to check kidney function before and during metformin treatment, with strict cutoffs at eGFR levels of 30 and 45.
Long-term use can quietly drain vitamin B12, with trials showing a meaningful share of patients dropping to abnormal levels.
The American Diabetes Association’s 2026 Standards of Care still name metformin the only drug specifically recommended for preventing type 2 diabetes.
Decades of federal prescribing data confirm metformin’s position as the most-used oral diabetes drug in the country, even as newer options gain ground.

A Pill Taken By Millions, Governed By Strict Rules

Metformin has been a cornerstone of type 2 diabetes care since the 1990s, and the prescribing numbers back up its reputation as a workhorse drug. Federal data tracking outpatient prescriptions from 2009 through 2015 found metformin made up 70 to 72 percent of all non-insulin diabetes prescriptions, totaling 217 million fills, more than any other class tracked. A separate federal analysis estimated over 553 million metformin prescriptions dispensed nationwide between 2000 and 2015, with volume climbing steadily that entire period.

That popularity comes with conditions many patients never hear spelled out clearly. The Food and Drug Administration’s official labeling instructs doctors to check a patient’s estimated glomerular filtration rate, or eGFR, a measure of kidney function, before ever starting the drug. The label bans starting metformin below an eGFR of 30 and advises against starting it between 30 and 45, because the kidneys are what clear the drug from the body.

Why Kidney Function Decides Who Can Safely Take It

The kidney rule exists for a specific reason. Metformin leaves the body almost entirely through the kidneys, and when kidney function slows down, the drug can build up in the bloodstream. Federal labeling for Glucophage, one of metformin’s original brand names, states plainly that this buildup raises the risk of lactic acidosis, a rare but serious condition where acid accumulates faster than the body can clear it. That is precisely why routine kidney testing is not optional paperwork but a built-in safety check.

This is not a new concern invented to scare patients off a cheap generic drug. It is baked into the prescribing information doctors are legally required to follow every time they write a refill. Patients with diabetes often already have some degree of kidney strain from the disease itself, which makes the testing requirement a practical safeguard rather than a bureaucratic formality.

The Vitamin Deficiency Few Patients Are Warned About

Long-term metformin use carries a second, quieter issue: vitamin B12 depletion. The FDA label states metformin may lower B12 levels and recommends checking levels every two to three years. In a 29-week clinical trial cited in the label, roughly 7 percent of patients dropped to subnormal B12 levels. A broader meta-analysis of randomized trials found a lower but still notable 1.4 percent deficiency rate after at least a year of use, while a separate pharmacological review flagged B12 deficiency as more common in patients on higher doses or longer treatment courses.

Low B12 can cause fatigue, nerve tingling, and memory problems, symptoms that get confused for aging or diabetes complications themselves. A simple blood test catches it early, yet the testing interval written into the label suggests this is a slow-building risk, not an emergency. Patients who have taken metformin for years without ever having B12 checked are not following an edge case; they are missing a standard recommendation.

Why Doctors Still Reach For It First

Despite newer drug classes like SGLT2 inhibitors and GLP-1 medications gaining rapid traction, especially among Medicare patients where SGLT2 prescribing jumped fivefold between 2014 and 2018, metformin has not been dethroned. The American Diabetes Association’s 2026 Standards of Care continue to list metformin as the only medication specifically recommended for preventing type 2 diabetes in high-risk patients.

That institutional endorsement matters. Metformin is inexpensive, decades-tested, and backed by a mountain of outcomes data that newer, costlier drugs are still accumulating. The honest takeaway is not that metformin is dangerous or outdated. It is that a drug this common deserves the same attentive follow-up as any newer medication, kidney checks and B12 tests included, rather than being treated as a lifetime prescription nobody needs to revisit.